/
Neurology
Huntington Disease
8
Pipeline Programs↗
9
Active Trials↗
10
Companies Involved↗
Huntington disease is an early-stage landscape with 8 programs across 10 companies. The most active players are Skyhawk Therapeutics, Inc., Ultragenyx, Neurocrine Biosciences. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 1
No programs
Phase 21
Approved
No programs
Analysis
Modality Breakdown
86%
Small molecule
6 of 7 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 88% of 8 pipeline programs.
Analysis
Trial Status
25
clinical trials
Completed14 · 56%
Active, not recruiting4 · 16%
Recruiting4 · 16%
Terminated2 · 8%
Enrolling by invitation1 · 4%
Clinical Trials
Trial Activity
25 trials
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)